Table 2.

Emerging Therapies

Drugs	Proposed Mechanism	NCT Identifier	Clinical trial
Vasodilators
Sapropterindihydrochloride (6R- BH4)	Increase Nitric oxide	NCT00435331	Phase I
Selexipag	Non-prostanoid IP receptor agonist	NCT01106014	Phase III
Inhaled nitric oxide	Increase Nitric oxide	NCT01457781	Phase II
Beet Juice	Increase Nitric oxide	NCT02000856	Phase I
Apelin	Increase Apelin levels with infusion	NCT01590108	Phase I
Cardizem	Calcium Channel Blockade	NCT01645826	Phase III
Inhaled Nitrite	Increase Nitric oxide	NCT01431313	Phase II
Ranolazine	Inhibition of Sodium Current	NCT01757808	Phase I
		NCT01953965	Phase II
Metabolism
Dichloroacetate	Inhibition of of Pyruvate Dehydrogenase Kinase	NCT01083524	Phase I
Anastrazole	Aromatase Inhibitors	NCT01545336	Phase II
Ferinject	Target Iron deficiency	NCT01288651	Phase II
Right Ventricular Remodeling
Carvediol	HIF activation, NO synthesis, beta-adrenergic recovery	receptor	NCT01586156 Phase II
Cell Damage/ endothelial dysfunction
Coenzyme Q-10	Antioxidant	NCT01148836	unkown
(−)-Epicatechin	Improvement of endothelial function	NCT01880866	Phase I
Anti-Proliferative
Sorafenib	Inhibition of protease-activated receptor (PAR)	NCT00452218	Phase I
Hydroxyurea	Decrease level of circulating immature bone marrow cells	NCT01950585	Phase 0
Nilotinib	Tyrosin Kinase Inhibitor	NCT01179737	Phase II
Anti-Inflammatory
Rituximab	Restore B-cell dysregulation	NCT01086540	Phase II
Bardoxolone Methyl	Nrf2 and NF-κB suppression	NCT02036970	Phase II
Saquinavir and Ritonavir	HIV protease inhibitors	NCT02023450	Phase 0
TheraSorb® Ig flex adsorber	Immunoabsorption	NCT01613287	Medical Device
BMPR2 modulators
FK506	Increasing BMPR2 signaling	NCT01647945	Phase II